72
Participants
Start Date
October 13, 2021
Primary Completion Date
December 10, 2023
Study Completion Date
June 4, 2025
Bone marrow mesenchymal stem cells
The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
hyaluronic acid
(60 mg/3 mL hyaluronic acid \[HA\])
Taipei Veterans General Hospital, Taipei
Taipei Municipal Wangfang Hospital (Managed by Taipei Medical University), Taipei
A2 Healthcare Taiwan Corporation
INDUSTRY
Taiwan Bio Therapeutics Inc.
INDUSTRY